Investigation of GTT Communications
GTT Communications, Inc. (GTT) Accused of Misleading Investors According to the complaint, for alleged violations of the Securities Exchange Act of 1934 between February 26, 2018 and July 1, 2019,
GTT Communications, Inc. (GTT) Accused of Misleading Investors According to the complaint, for alleged violations of the Securities Exchange Act of 1934 between February 26, 2018 and July 1, 2019,
Robbins LLP is Investigating the Officers and Directors of National Beverage Corp. (FIZZ) on behalf of Shareholders Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors
Aclaris Therapeutics, Inc. (ACRS) Accused of Making Misleading Claims in Video Advertisement According to the complaint for alleged violations of the Securities Exchange Act of 1934 between May 8, 2018
Robbins LLP is Investigating Greenlane Holdings, Inc. (GNLN) Shareholder rights law firm Robbins LLP informs shareholders that it is investigating Greenlane Holdings, Inc. (NASDAQ: GNLN) for potential violations of federal
American Renal Associates Holdings, Inc. (ARA) Accused of Improper Revenue Recognition According to the complaint, American Renal Associates Holdings, Inc’s (ARA) officers and directors breached their fiduciary duties by failing
GrubHub, Inc. (GRUB) Accused of Unlawful Business Practices On July 15, 2019, The New Food Economy reported that Grubhub, Inc (GRUB) registered more than 20,000 web domains, many matching the
National General Holdings Corp. (NGHC) Accused of Participating in Fraudulent Insurance Scheme According to the complaint, for alleged violations of the Securities Exchange Act of 1934 between August 6, 2015
Vanda Pharmaceuticals Inc. (VNDA) Used its Drugs for Off-Label Purposes According to the complaint, since November 2015, Vanda Pharmaceuticals Inc (VNDA) and its officers have breached their fiduciary duties by
Karyopharm Therapeutics Inc. (KPTI) Accused of Misleading Investors According to the complaint, in March 2017, Karyopharm reported that its interim results from its SORPA study of selinexor did not reach
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2024 – Robbins LLP
Stock Watch members receive free investment monitoring and notifications.